We are a swiss technology company that has developed the First Autonomous robotic platform for establishing an human eye and machine physical interaction. As our initial use case, we are focused on the treatment for chronic degenerative retinal diseases, but why ? Imagine your vision suddenly turns blurry. This blurry vision repeats and increases until you become blind. Losing the ability to drive, read, or see their loved ones, with the subsequent trauma for them and their families, is today’s reality for over 335 million people around the world suffering from visual impairment triggered by chronic retinal diseases through age (Dry & Wet AMD) or diabetes (DR, DME, DRVO). Since 2006 the treatable diseases among the list are treated with the so-called Anti VGEF drugs, which are delivered through manual injections between eight and ten times per year for life. At Ophthorobotics we are determined to give treatment access to any patient anywhere in the world, and improving their patient experience, through transformative treatments across the care continuum, leveraging robotically-assisted technology and digital health. Our patented technology is enabling the first direct human and machine physical interaction in Ophthalmology overall, capable of autonomously perform injections safely. Considering the chronic nature of these five diseases, where patients receive treatment for decades, we have combined robotics with our Digital Health capabilities to create more effective, convenient, and safer treatments across the care continuum. With our innovations, considering that patient population will grow by 25% over the next decade, we aspire to contribute to the long-term sustainability of healthcare systems through Optimizing treatment capacity, reducing total cost of Care and maximizing Ophthalmic Patients Value.